Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (475.98%) | (1,497.43%) | (38,510.54%) | (288.67%) | ||
| (144.19%) | (188.01%) | (193.68%) | (117.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
83,014.58% | (955.85%) | (592.44%) | (211.25%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.78) | (0.91) | (0.92) | (1.88) | |
Free Cash Flow |
(59.45) | (68.58) | (69.94) | (68.42) | |
Capital Expenditures |
— | — | — | (3.34) | |
| Other line items | |||||
Cash ROIC |
(580.81%) | 4,703.43% | 2,602.94% | (106.33%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 7.06 | |
Accounts Payable Turnover |
0.12 | 0.20 | 0.13 | 0.20 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
2,249.31 | 1,616.55 | 4,034.77 | 2,856.45 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
763.23% | 688.70% | 732.50% | 732.60% | |
Selling, General and Administrative Expense of Revenue |
184.19% | 138.99% | 140.91% | 142.67% | |
Share Based Compensation of Revenue |
33.12% | 28.97% | 27.56% | 28.02% | |
Interest Coverage |
(40.57) | (47.83) | (66.44) | (108.48) | |
Operating CF/Net income |
1.49 | 0.89 | 0.62 | 0.85 | |
Depreciation/Fixed assets |
5.27 | 4.31 | 3.66 | 3.28 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (3.77) | |
Revenue per Share |
0.09 | 0.12 | 0.13 | 0.25 | |
Operating CF per Share |
(0.78) | (0.91) | (0.92) | (1.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.09) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.37 |
Columns are period end dates